This document is a publication of a European Patent Office (EPO) patent application, EP4563143A1, titled 'A BILAYER TABLET FORMULATION OF METFORMIN AND SITAGLIPTIN COMPRISING ANTIOXIDANT'. The application, filed by Sanovel Ilac Sanayi ve Ticaret A.S., details a specific pharmaceutical formulation for co-administering Metformin and Sitagliptin in a bilayer tablet, incorporating an antioxidant to potentially improve stability or efficacy. The publication date is March 18, 2026.

As this is a patent application publication, it does not impose direct regulatory obligations or compliance deadlines on pharmaceutical companies. However, it signifies potential new intellectual property in the diabetes treatment space. Companies involved in the manufacturing or development of diabetes medications, particularly those using Metformin and Sitagliptin, should be aware of this filing as it may impact future market exclusivity and product development strategies. The designated states indicate the patent's potential geographic coverage within Europe.